Translate biology insights into genetic medicines.
Microbes Microbes

Developing a COVID Vaccine or Therapeutic?


PNI’s COVID-19 Solutions can help you to develop and manufacture RNA nanomedicine vaccines and therapeutics faster and more reliably 


We Offer an Integrated Suite of Proprietary Technology, Nanomedicine Expertise & Custom Services: 

Scale-up and manufacturing technology for your RNA-LNPs therapeutics

Proprietary lipids formulations (RNA delivery technology) for your formulation

Expertise and support in formulation development, optimization, and planning scale-up and tech transfer for GMP manufacturing

Joint efforts to seek available funding for co-development of COVID-19 RNA-LNP vaccine

Formulation Solutions Formulation Solutions Formulation Solutions
Rapidly prepare low-volume nanoparticle formulations with the push of a button on the Spark™ or learn how Formulation Solutions can help with proof-of-concept nanoparticle formulations.
Optimize a wide range of nanomedicine formulations with the NanoAssemblr® Ignite or the Blaze  depending on your volumes to allow you to gather the data on the effectiveness, required dosing and safety of a new therapy.
Scalable manufacturing is a significant challenge to making revolutionary medicine and  Clinical Solution  is ready to assist you in your nanoparticle manufacturing process development.
of top pharmaceutical companies work with PNI

instruments are installed


biopharmaceutical labs use NanoAssemblr® instruments for nanomedicine drug development
Innovations that accelerate the drug development journey and enable the production of more sophisticated and powerful nanomedicines is our passion. We don’t do it alone, we pursue strategic collaborations that enable researchers to move quickly in the drug development process. Contact our Business Development Team.







CaSino Biologics and Precision NanoSystems Announced a Collaboration to Co-Develop a Covid-19 RNA Vaccine

PNI will lead development of the mRNA-LNP vaccine: RNA Vaccine Development, LNP Formulations and NanoAssemblr technology.

Entos and Precision NanoSystems Partner to Enable GMP Manufacturing of DNA COVID-19 Vaccine


"Using their GMP System will let us meet the challenge of producing our pan-coronavirus DNA vaccine at large scale and in as short a time as possible, while exceeding all safety and quality requirements."

John Lewis, Entos CEO

Clinical Solutions Platform Launch


“Clinical Solutions is designed to provide a one-stop-shop for all nanomedicine clinical development needs, such as sourcing GMP excipients, developing analytical methods, building Quality Management Systems or accessing experienced Contract Manufacturing Organizations,” Precision NanoSystems' CCO, Euan Ramsay

Vials Machine

Get Started

To learn how Precision NanoSystems accelerates nanomedicine development from an idea to clinical applications, contact our Technical Sales Team.

Get in Touch

NxGen logo


Our exclusive NxGen technology uses precisely controlled mixing to reproducibly generate optimal particles through a single mixer across scales. NxGen technology is at the heart of the NanoAssemblr® family, which provides manufacturing of nanoparticles at different scales suitable for all stages of nanomedicine development.

 Learn More.


Areas of Interest
Nanomedicines span many areas of interest. Explore resourceslike papers, application notes, scientific posters, webinars and more to see how nanotechnology is transforming medicine. 
You're In Good Company


  • “The NanoAssemblr® Blaze™ from Precision NanoSystems is very good for the rapid scale-up of nanoparticle-based formulations. We were able to seamlessly transition our formulation developed on the NanoAssemblr Benchtop to the Blaze instrument and make large scale batches on the Blaze. The Blaze instrument has saved us time, effort and precious materials.” - Muthusamy Jayaraman Senior Director, Head of Non-Viral Delivery at CRISPR Therapeutics
  • "As an Evonik affiliate specialized in liposomal drug delivery systems, we are pleased to offer our clients access to the NanoAssemblr GMP System, which will aid in the translation of drug candidates to clinical testing and ideally to commercial use."  - Don Enns, Vice President of Evonik Vancouver Laboratories
  • "We are excited about this promising collaboration and hope that it will propel our work forward as the ncRNA Core Facility focuses on the non-coding RNA portions of the genome for [the] discovery of novel biomarkers and targets for therapeutics from human disease tissue and clinical trial specimens."- Frank Slack, Director of the Harvard Medical School Initiative for RNA Medicine (HIRM) at BIDMC
  • "Ajinomoto Bio-Pharma Services has audited the PNI facilities in Vancouver and has qualified PNI's NanoAssemblr® GMP System and its components. We are excited to work with PNI to offer their purpose-designed manufacturing technology and unique nanomedicine expertise to our clients for the manufacture of nanoparticle-based medicines"  - Kristin DeFife, Ph.D., Vice President and Head of US Operations of Ajinomoto Bio-Pharma Services

Upcoming Events See All


Resource Center


September 01, 2022

Scale Up Genome Editing of CAR T Cells using Lipid Nanoparticles

Read More 阅读更多 PDF

Application Note

March 15, 2022

Genome Editing of Human Primary T Cells with Lipid Nanoparticles

Read More 阅读更多 PDF

Publication - Abstract

July 01, 2020

Journal of Controlled Release

Delivery of Self-amplifying mRNA Vaccines by Cationic Lipid Nanoparticles: The Impact of Cationic Lipid Select...

G. Lou, G. Anderluzzi, S.T. Schmidt, S. Woods, S. Gallorini, M. Brazzoli, F. Giusti, I. F...

Read More 阅读更多

Publication - Abstract

May 08, 2020


Investigating the Impact of Delivery System Design on the Efficacy of Self-Amplifying RNA Vaccines

G. Anderluzzi, G. Lou, S. Gallorini, M. Brazzoli, R. Johnson, D.T. O'Hagan, B.C. Baudner a...

Read More 阅读更多

Publication - Abstract

April 02, 2020

Journal of Controlled Release

Design of a Novel Vaccine Nanotechnology-based Delivery System Comprising CpGODN-protein Conjugate Anchored to...

D. Chatzikleanthous, S.T. Schmidt, G. Buffi, I. Paciello, R. Cunliffe, F. Carboni, M.R. Ro...

Read More 阅读更多

Publication - Abstract

December 31, 2019


Investigating Prime-Pull Vaccination through a Combination of Parenteral Vaccination and Intranasal Boosting

C.B. Roces, M.T. Hussain, S.T. Schmidt, D. Christensen and Y. Perrie

Read More 阅读更多
Resource Center 资源中心

Stay Informed

Sign up today to automatically receive new Cytiva, formerly Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.